The use of HA oligosaccharide-loaded nanoparticles to breach the endogenous hyaluronan glycocalyx for breast cancer therapy

Biomaterials

Volumn 34, Issue 28, 2013, Pages 6829-6838

  Yang, Cuixia ^a   Liu, Yiwen ^a   He, Yiqing ^a   Du, Yan ^a   Wang, Wenjuan ^a   Shi, Xiaoxing ^b   Gao, Feng ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Department of Laboratory Medicine   (China)

Author keywords

Breast cancer; Drug carrier; Hyaluronan coat; Oligosaccharides

Indexed keywords

ANTI-TUMOR ACTIVITIES; BREAST CANCER; BREAST CANCER CELLS; DRUG CARRIER; EXTRACELLULAR MATRICES; HYALURONAN; MICROENVIRONMENTS; RESEARCH EFFORTS;

CHEMOTHERAPY; DISEASES; NANOPARTICLES; OLIGOSACCHARIDES; ONCOLOGY; PHARMACODYNAMICS; TUMORS;

HYALURONIC ACID;

ANTINEOPLASTIC AGENT; HYALURONIC ACID; NANOCARRIER; OLIGOSACCHARIDE; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER THERAPY; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG COATING; DRUG TARGETING; ERYTHROCYTE; EXTRACELLULAR MATRIX; GLYCOCALYX; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR XENOGRAFT; ZETA POTENTIAL;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG CARRIERS; GLYCOCALYX; HUMANS; HYALURONIC ACID; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; NANOPARTICLES; OLIGOSACCHARIDES;

EID: 84879459539     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.05.036     Document Type: Article

References (51)

1. Ribeiro J., Macedo L., Curigliano G., Fumagalli L., Locatelli M., Dalton M., et al. Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future?. Ann Oncol 2012, 23(3):547-555.
2. Cardoso F., Di Leo A., Lohrisch C., Bernard C., Ferreira F., Piccart M. Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?. Ann Oncol 2002, 13(2):197-207.
3. Olive K.P., Jacobetz M.A., Davidson C.J., Gopinathan A., McIntyre D., Honess D., et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324(5933):1457-1461.
4. Olson P., Hanahan D. Breaching the cancer fortress. Science 2009, 324(5933):1400-1401.
5. Toole B.P., Wight T.N., Tammi M.I. Hyaluronan-cell interactions in cancer and vascular disease. JBiol Chem 2002, 277(7):4593-4596.
6. Bertrand P., Girard N., Delpech B., Duval C., d'Anjou J., Dauce J. Hyaluronan (hyaluronic acid) and hyaluronectin in the extracellular matrix of human breast carcinomas: comparison between invasive and noninvasive areas. Int J Cancer 1992, 52(1):1-6.
7. Wernicke M., Pineiro L.C., Caramutti D., Dorn V.G., Raffo M.M.L., Guixa H.G., et al. Breast cancer stromal myxoid changes are associated with tumor invasion and metastasis: a central role for hyaluronan. Mod Pathol 2003, 16(2):99-107.
8. Auvinen P., Tammi R., Parkkinen J., Tammi M., Ågren U., Johansson R., et al. Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am J Pathol 2000, 156(2):529.
9. Suwiwat S., Ricciardelli C., Tammi R., Tammi M., Auvinen P., Kosma V.M., et al. Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer. Clin Cancer Res 2004, 10(7):2491-2498.
10. Casalini P., Carcangiu M.L., Tammi R., Auvinen P., Kosma V.M., Valagussa P., et al. Two distinct local relapse subtypes in invasive breast cancer: effect on their prognostic impact. Clin Cancer Res 2008, 14(1):25-31.
11. Bollyky P.L., Wu R.P., Falk B.A., Lord J.D., Long S.A., Preisinger A., et al. ECM components guide IL-10 producing regulatory T-cell (TR1) induction from effector memory T-cell precursors. Proc Natl Acad Sci U S A 2011, 108(19):7938-7943.
12. Thompson C.B., Shepard H.M., O'Connor P.M., Kadhim S., Jiang P., Osgood R.J., et al. Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models. Mol Cancer Ther 2010, 9(11):3052-3064.
13. Feig C., Gopinathan A., Neesse A., Chan D.S., Cook N., Tuveson D.A. The pancreas cancer microenvironment. Clin Cancer Res 2012, 18(16):4266-4276.
14. LaBarge M.A. The difficulty of targeting cancer stem cell niches. Clin Cancer Res 2010, 16(12):3121-3129.
15. Rilla K., Tiihonen R., Kultti A., Tammi M., Tammi R. Pericellular hyaluronan coat visualized in live cells with a fluorescent probe is scaffolded by plasma membrane protrusions. JHistochem Cytochem 2008, 56(10):901-910.
16. Itano N., Zhuo L., Kimata K. Impact of the hyaluronan-rich tumor microenvironment on cancer initiation and progression. Cancer Sci 2008, 99(9):1720-1725.
17. Eikenes L., Tufto I., Schnell E.A., Bjørkøy A., Davies C.D.E.L. Effect of collagenase and hyaluronidase on free and anomalous diffusion in multicellular spheroids and xenografts. Anticancer Res 2010, 30(2):359-368.
18. Ricciardelli C., Russell D.L., Ween M.P., Mayne K., Suwiwat S., Byers S., et al. Formation of hyaluronan-and versican-rich pericellular matrix by prostate cancer cells promotes cell motility. JBiol Chem 2007, 282(14):10814-10825.
19. Baumgartner G., Gomar-Höss C., Sakr L., Ulsperger E., Wogritsch C. The impact of extracellular matrix on the chemoresistance of solid tumors-experimental and clinical results of hyaluronidase as additive to cytostatic chemotherapy. Cancer Lett 1998, 131(1):85-99.
20. Brekken C., de Lange Davies C. Hyaluronidase reduces the interstitial fluid pressure in solid tumours in a non-linear concentration-dependent manner. Cancer Lett 1998, 131(1):65-70.
21. Ganesh S., Gonzalez-Edick M., Gibbons D., Van Roey M., Jooss K. Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models. Clin Cancer Res 2008, 14(12):3933-3941.
22. Whatcott C.J., Han H., Posner R.G., Hostetter G., Von Hoff D.D. Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look. Cancer Discov 2011, 1(4):291-296.
23. Du L., Wang H., He L., Zhang J., Ni B., Wang X., et al. CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res 2008, 14(21):6751-6760.
24. Kayastha S., Freedman A.N., Piver M.S., Mukkamalla J., Romero-Guittierez M., Werness B.A. Expression of the hyaluronan receptor, CD44S, in epithelial ovarian cancer is an independent predictor of survival. Clin Cancer Res 1999, 5(5):1073-1076.
25. Rupp U., Schoendorf-Holland E., Eichbaum M., Schuetz F., Lauschner I., Schmidt P., et al. Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study. Anticancer Drugs 2007, 18(4):477-485.
26. Sauter A., Kloft C., Gronau S., Bogeschdorfer F., Erhardt T., Golze W., et al. Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck. Int J Oncol 2007, 30(4):927.
27. Riechelmann H., Sauter A., Golze W., Hanft G., Schroen C., Hoermann K., et al. Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. Oral Oncol 2008, 44(9):823-829.
28. Pályi-Krekk Z., Barok M., Kovács T., Saya H., Nagano O., Szöllosi J., et al. EGFR and ErbB2 are functionally coupled to CD44 and regulate shedding, internalization and motogenic effect of CD44. Cancer Lett 2008, 263(2):231-242.
29. Palyi-Krekk Z., Barok M., Isola J., Tammi M., Szollosi J., Nagy P. Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer. Eur J Cancer 2007, 43(16):2423-2433.
30. Toole B.P., Slomiany M.G. Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells. Semin Cancer Biol 2008, 18:244-250.
31. Lennon F.E., Singleton P.A. Hyaluronan regulation of vascular integrity. Am J Cardiovasc Dis 2011, 1(3):200-213.
32. Yang C., Cao M., Liu H., He Y., Xu J., Du Y., et al. The high and low molecular weight forms of hyaluronan have distinct effects on CD44 clustering. JBiol Chem 2012, 287(51):43094-43107.
33. Toole B.P. Hyaluronan-CD44 interactions in cancer: paradoxes and possibilities. Clin Cancer Res 2009, 15(24):7462-7468.
34. Rivkin I., Cohen K., Koffler J., Melikhov D., Peer D., Margalit R. Paclitaxel-clusters coated with hyaluronan as selective tumor-targeted nanovectors. Biomaterials 2010, 31(27):7106-7114.
35. Bachar G., Cohen K., Hod R., Feinmesser R., Mizrachi A., Shpitzer T., et al. Hyaluronan-grafted particle clusters loaded with Mitomycin C as selective nanovectors for primary head and neck cancers. Biomaterials 2011, 32(21):4840-4848.
36. Platt V.M., Szoka F.C. Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharm 2008, 5(4):474-486.
37. Slomiany M.G., Dai L., Bomar P.A., Knackstedt T.J., Kranc D.A., Tolliver L., et al. Abrogating drug resistance in malignant peripheral nerve sheath tumors by disrupting hyaluronan-CD44 interactions with small hyaluronan oligosaccharides. Cancer Res 2009, 69(12):4992-4998.
38. Lesley J., Hascall V.C., Tammi M., Hyman R. Hyaluronan binding by cell surface CD44. JBiol Chem 2000, 275(35):26967-26975.
39. Gao F., Cao M., Yang C., He Y., Liu Y. Preparation and characterization of hyaluronan oligosaccharides for angiogenesis study. JBiomed Mater Res B 2006, 78(2):385-392.
40. Lee S.J., Ghosh S.C., Han H.D., Stone R.L., Bottsford-Miller J., Shen de Y., et al. Metronomic activity of CD44-targeted hyaluronic acid-paclitaxel in ovarian carcinoma. Clin Cancer Res 2012, 18(15):4114-4121.
41. Banzato A., Bobisse S., Rondina M., Renier D., Bettella F., Esposito G., et al. Apaclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent invivo therapeutic activity. Clin Cancer Res 2008, 14(11):3598-3606.
42. Weigand S., Herting F., Maisel D., Nopora A., Voss E., Schaab C., et al. Global quantitative phosphoproteome analysis of human tumor xenografts treated with a CD44 antagonist. Cancer Res 2012, 72(17):4329-4339.
43. Jacobetz M.A., Chan D.S., Neesse A., Bapiro T.E., Cook N., Frese K.K., et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 2013, 62:112-120.
44. Tammi R.H., Kultti A., Kosma V.M., Pirinen R., Auvinen P., Tammi M.I. Hyaluronan in human tumors: pathobiological and prognostic messages from cell-associated and stromal hyaluronan. Semin Cancer Biol 2008, 18(4):288-295.
45. Provenzano P.P., Cuevas C., Chang A.E., Goel V.K., Von Hoff D.D., Hingorani S.R. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012, 21(3):418-429.
46. Fukumura D., Jain R.K. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. JCell Biochem 2006, 101(4):937-949.
47. Lieleg O., Ribbeck K. Biological hydrogels as selective diffusion barriers. Trends Cell Biol 2011, 21(9):543-551.
48. Nishida Y., Knudson W., Knudson C.B., Ishiguro N. Antisense inhibition of hyaluronan synthase-2 in human osteosarcoma cells inhibits hyaluronan retention and tumorigenicity. Exp Cell Res 2005, 307(1):194-203.
49. Hosono K., Nishida Y., Knudson W., Knudson C.B., Naruse T., Suzuki Y., et al. Hyaluronan oligosaccharides inhibit tumorigenicity of osteosarcoma cell lines MG-63 and LM-8 invitro and invivo via perturbation of hyaluronan-rich pericellular matrix of the cells. Am J Pathol 2007, 171(1):274-286.
50. Gilg A.G., Tye S.L., Tolliver L.B., Wheeler W.G., Visconti R.P., Duncan J.D., et al. Targeting hyaluronan interactions in malignant gliomas and their drug-resistant multipotent progenitors. Clin Cancer Res 2008, 14(6):1804-1813.
51. Slomiany M.G., Dai L., Tolliver L.B., Grass G.D., Zeng Y., Toole B.P. Inhibition of functional hyaluronan-CD44 interactions in CD133-positive primary human ovarian carcinoma cells by small hyaluronan oligosaccharides. Clin Cancer Res 2009, 15(24):7593-7601.